# A Study of Belimumab in Subjects With Systemic Lupus Erythematosus

> **NCT00410384** · PHASE3 · COMPLETED · sponsor: **Human Genome Sciences Inc.** · enrollment: 819 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Placebo
- **DRUG:** Belimumab 1 mg/kg
- **DRUG:** Belimumab 10 mg/kg

## Key facts

- **NCT ID:** NCT00410384
- **Lead sponsor:** Human Genome Sciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2009-09
- **Final completion:** 2010-03
- **Target enrollment:** 819 (ACTUAL)
- **Last updated:** 2017-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00410384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00410384, "A Study of Belimumab in Subjects With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00410384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*